R&D

Overview

AGM-331 AGM-130 AGM-380 AGM-290 AGM-212 AGM-217 AGM-260
Antidiabetic peptide drug AGM-212
AGM-212, a GLP-1 receptor agonist, comprised of the truncated part of exenatide with a fatty acid to improve the antidiabetic activity and its in vivo pharmacological profile
  • Exenatide
    • - Marketed as Byetta in 2007
    • - $14.7 billion (CAGR : 23%)

  • AGM-212 elicited slightly greater insulin secretion than exenatide in rat islets, which confirmed the strong insulinotropic activity of AGM-212.

  • AGM-212 which was subcutaneously injected into diabetic mice under non-fasting maintained normoglycemia for more than 40h post-injection.

  • The pharmacokinetic profiles of AGM-212 exhibited much longer half-life (2.25h) than exenatide (0.47h).